The GSDMD Knockout Ca Ski Polyclonal Cells are a CRISPR/Cas9 genome-edited polyclonal population derived from the Ca Ski human cervical squamous carcinoma epithelial cell line, with targeted disruption of the GSDMD gene. This heterogeneous knockout model avoids clonal selection, preserving the genetic diversity of the edited pool, and provides a robust system for functional studies of pyroptosis and inflammation. The polyclonal format minimizes single-cell cloning artifacts, making it suitable for population-based assays in drug screening and pathway analysis.
The host Ca Ski cell line is a well-characterized model of cervical cancer, originally isolated from a metastatic epidermoid carcinoma. These cells stably harbor integrated human papillomavirus types 16 and 18 (HPV16 and HPV18), leading to continuous expression of viral oncoproteins E6 and E7, which respectively target p53 and Rb for degradation. This HPV-mediated inactivation of key tumor suppressors drives unchecked proliferation and resistance to conventional apoptosis, establishing a context in which alternative cell death pathways, such as pyroptosis, may play critical roles.
GSDMD (gasdermin D) is the pore-forming executor of pyroptosis, a lytic programmed cell death pathway essential for inflammation. Canonical inflammasomes such as NLRP3 and AIM2 recruit the adaptor ASC (PYCARD) to activate caspase-1, while non-canonical pathways engage caspase-4/5/11 in response to cytosolic LPS. These inflammatory caspases cleave GSDMD, releasing its N-terminal domain, which oligomerizes into plasma membrane pores, enabling the secretion of IL-1?? and IL-18 and the release of HMGB1. The process culminates in cell lysis and is facilitated by NINJ1. Upstream, TAK1 kinase and the IKK complex modulate inflammasome priming.
In the Ca Ski background, GSDMD knockout provides a unique model to explore the role of pyroptosis in HPV-associated cervical carcinogenesis. Since viral oncoproteins suppress apoptosis, pyroptotic death may serve as a back-up tumor-suppressive mechanism or fuel inflammation-driven tumor progression. This knockout enables dissection of GSDMD??s impact on cytokine release, immune cell recruitment, and cell lysis within an oncogenic environment, and the dual HPV16/18 status allows comparative analysis of genotype-specific effects on inflammasome output.
Typical research applications include mechanistic investigations of pyroptosis in cervical cancer, high-throughput screening of small-molecule inflammasome modulators, and functional host-pathogen interaction studies using bacterial or viral challenges. Endpoint assays such as western blotting (for full-length and N-terminal GSDMD), LDH release, IL-1?? ELISA, flow cytometry with propidium iodide uptake, immunofluorescence for pore formation, and caspase-1 activity measurements are all compatible. This polyclonal population also supports RT-qPCR for transcriptional profiling of inflammasome components. For technical guidance or custom experimental design, contact Ascent Research.
